Drug Trial Radar · NCT00403793
Hormonal Contraception in Healthy Young Men (P42306)(COMPLETED)(P06057)
Last checked: Nov 19, 2026Latest source record: Feb 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
350
Actual
Start
Oct 2003
Primary completion
Dec 2006
Study completion Dec 2006
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- Collaborators
- Bayer
- First posted
- Nov 27, 2006
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Male volunteers receive a new hormonal contraceptive consisting of an implant releasing a hormone and hormone injections in order to investigate the suppressive effect on sperm production and reversibility of sperm production after end of treatment.
Conditions
- Contraception
Interventions
etonogestrel with testosterone undecanoateDrug
42 or 44 weeks with etonogestrel implant and testosterone undecanoate injections every 10 to 12 weeks
PlaceboDrug
42 or 44 weeks with placebo implant and placebo injections
Primary outcomes
What the sponsor says the trial is designed to measure.
- % of men who had a sperm concentration of 1 million/ml or less at week 16.Time frame: Week 16
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.